ライフサイエンスコーパス: positron emission

1 reduced brain network activities detected by positron-emission computed tomography (PET).

2 trols (n = 12) using in vivo high-resolution positron emission tomographic imaging as well as postmor

3 measured at baseline using [18F]florbetapir positron emission tomographic imaging.

4 penumbra detection against full quantitative positron emission tomography ((15) O-PET), the gold stan

5 erved clinically by (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET).

6 scaffold was studied as a template for (18)F-positron emission tomography ((18)F-PET) radiotracer dev

7 and 6 mo was measured with 18sodium fluoride positron emission tomography (18F-NaF PET) scans as targ

8 2-Deoxy-2-[18F]fluoro-D-glucose (2-FDG) with positron emission tomography (2-FDG-PET) is undeniably u

9 eceptor densities by using [(18)F]flumazenil positron emission tomography ([(18)F]FMZ-PET) and GABA c

10 ng been utilized in fluorodeoxyglucose-based positron emission tomography (FDG-PET) as a contrast mec

11 homa, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, afte

12 criteria with respect to fluorodeoxyglucose positron emission tomography (FDG-PET) response criteria

13 s underwent brain [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans.

14 canning on a simultaneous magnetic resonance-positron emission tomography (MR-PET) scanner with the s

15 ts who had a clinical evaluation and amyloid positron emission tomography (PET) (A), tau PET (T), and

16 inical risk stratification in the context of positron emission tomography (PET) -adapted treatment is

17 elds, especially that of an important cancer positron emission tomography (PET) agent [(18)F]5-fluoro

18 e investigate the potential of (18)F-mFBG, a positron emission tomography (PET) analogue of the (123)

19 sing fMRI and brain glucose metabolism using positron emission tomography (PET) and (18)F-fluorodeoxy

20 n mGluR5 availability in MTLE patients using positron emission tomography (PET) and [(11) C]ABP688, a

21 urteen participants were scanned twice using positron emission tomography (PET) and [(11)C]carfentani

22 Positron emission tomography (PET) and [(11)C]UCB-J, a r

23 Fluorodeoxyglucose (FDG) positron emission tomography (PET) and cardiac magnetic

24 (11)C]rifampin (administered as a microdose) positron emission tomography (PET) and computed tomograp

25 ardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk.

26 ivo at the subfield level using simultaneous positron emission tomography (PET) and magnetic resonanc

27 Two longitudinal flortaucipir (FTP) positron emission tomography (PET) and magnetic resonanc

28 We combined [(11)C]PK11195 positron emission tomography (PET) and resting-state fun

29 Positron emission tomography (PET) and single-photon ima

30 Using positron emission tomography (PET) and the [(18)F]AV1451

31 Here, we provide a brief overview of positron emission tomography (PET) applications that cou

32 ce imaging (MRI) and (64)Cu-DOTA-trastuzumab positron emission tomography (PET) are used to estimate

33 y naltrexone measured with [(11)C]-LY2795050 positron emission tomography (PET) as a predictor of res

34 (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography (PET) at baseline and 6 mon

35 Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloi

36 (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can detect vascular i

37 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) combined with compute

38 Dosimetry models using preclinical positron emission tomography (PET) data are commonly emp

39 Amyloid positron emission tomography (PET) detects amyloid plaqu

40 approved cerebrospinal fluid or amyloid beta positron emission tomography (PET) diagnostic tests.

41 nt chemical scaffolds in pharmaceuticals and positron emission tomography (PET) diagnostics.

42 and JHU37160, and the first dedicated (18)F positron emission tomography (PET) DREADD radiotracer, [

43 Positron emission tomography (PET) enables non-invasive

44 iffusion weighted imaging (DWI), and dynamic positron emission tomography (PET) for detection of meta

45 on emission computed tomography (SPECT), and positron emission tomography (PET) for ischemia diagnosi

46 measurement of receptor occupancy (RO) using positron emission tomography (PET) has been instrumental

47 ns between cerebral blood flow (CBF) and tau positron emission tomography (PET) images in independent

48 Aspiring to develop a positron emission tomography (PET) imaging agent for the

49 Herein, we report a (64)Cu positron emission tomography (PET) imaging agent that sh

50 We investigated whether positron emission tomography (PET) imaging allows identi

51 pecific for mHTT aggregates could serve as a positron emission tomography (PET) imaging biomarker for

52 Moreover, by employing (64)Cu(2+), positron emission tomography (PET) imaging can be achiev

53 Towards this end, positron emission tomography (PET) imaging has emerged a

54 In vivo positron emission tomography (PET) imaging is a key moda

55 s (13-15) have been synthetized as potential positron emission tomography (PET) imaging ligands for m

56 Positron emission tomography (PET) imaging of the 18 kDa

57 Past acetylcholinesterase positron emission tomography (PET) imaging studies impli

58 We selected subjects from a previous positron emission tomography (PET) imaging study in epil

59 OPA) is a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging that is used

60 e levels of mGlu5 receptor availability with positron emission tomography (PET) imaging using the mGl

61 We here use in vivo positron emission tomography (PET) imaging, flow cytomet

62 (FTP) and (11)C-Pittsburgh compound-B (PiB) positron emission tomography (PET) imaging, we measured

63 acking of Abeta accumulation with [(11)C]PiB positron emission tomography (PET) imaging.

64 , an activatable MPO activity radioprobe for positron emission tomography (PET) imaging.

65 s radiopharmaceuticals and (86)Y tracers for positron emission tomography (PET) imaging.

66 luorides are widely used as radiotracers for positron emission tomography (PET) imaging.

67 vivo neuroinflammation using [(11)C]PK11195 positron emission tomography (PET) imaging.

68 ring probe [C-11]-(+)-PHNO was measured with positron emission tomography (PET) in 79 human subjects

69 Positron emission tomography (PET) is a diagnostic nucle

70 Positron emission tomography (PET) is a molecular imagin

71 Radiomics using 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising approa

72 Positron emission tomography (PET) is an important imagi

73 Arterial (18)fluorodeoxyglucose (FDG) positron emission tomography (PET) is considered a measu

74 The availability of a MAGL-specific positron emission tomography (PET) ligand would consider

75 ed tomography (CT) compared with rubidium-82 positron emission tomography (PET) MBF estimates in a hi

76 Here, we create a non-invasive positron emission tomography (PET) methodology to track

77 Fluorine-18 flurpiridaz is a novel positron emission tomography (PET) myocardial perfusion

78 panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau pathologies in

79 Positron emission tomography (PET) plays key roles in dr

80 Coronary (18)F-sodium fluoride ((18)F-NaF) positron emission tomography (PET) provides an assessmen

81 Positron emission tomography (PET) provides quantitative

82 ated analogue of the previously reported CB2 positron emission tomography (PET) radioligand [(11)C]RS

83 relates minute-by-minute fluctuations of the positron emission tomography (PET) radioligand [11C]racl

84 [(11)C]carfentanil, a selective MOR agonist positron emission tomography (PET) radioligand, to inves

85 Positron emission tomography (PET) radioligands (radioac

86 scribes the radiolabeling of biotin with the positron emission tomography (PET) radionuclide carbon-1

87 ng cancer in vivo using a voltage-sensitive, positron emission tomography (PET) radiotracer known as

88 nd-of-treatment (EOT) 18F-fluorodeoxyglucose positron emission tomography (PET) scan to guide consoli

89 with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the

90 All subjects underwent positron emission tomography (PET) scans with two differ

91 ive features for AD classification using tau positron emission tomography (PET) scans.

92 We examined (18) F-Flortaucipir (FTP)-positron emission tomography (PET) signal across 41 cort

93 logy and treatment of anxiety disorders, but positron emission tomography (PET) studies probing the t

94 In the current positron emission tomography (PET) study, we evaluated t

95 217 shows stronger correlations with the tau positron emission tomography (PET) tracer [(18)F]flortau

96 (18)F-PI-2620 is a positron emission tomography (PET) tracer with high bind

97 Recent advances in positron emission tomography (PET) tracers now enable in

98 Positron emission tomography (PET) tracers that bind to

99 (68)Ga-DOTA-Tyr3-octreotide ((68)Ga-DOTATOC) positron emission tomography (PET) tumor uptake and volu

100 Positron emission tomography (PET) uses radiotracers to

101 Background Positron emission tomography (PET) using (18)F-sodium fl

102 ication-free participants with MDD underwent positron emission tomography (PET) using [(11)C]CUMI-101

103 tandard (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) viability.

104 dardized uptake value ratios (SUVRs) for tau positron emission tomography (PET) were compared among 1

105 MRI data and a subset (n = 90) with amyloid positron emission tomography (PET) were included.

106 [(11)C]NOP-1A and positron emission tomography (PET) were used to measure

107 riatal D(2) receptor binding (examined using positron emission tomography (PET) with (11)C-raclopride

108 e present study was to validate and optimize positron emission tomography (PET) with (11)C-vorozole f

109 lopment of radioligands for Y(1)R imaging by positron emission tomography (PET) with a special emphas

110 ment after several antibiotic therapiesand a positron emission tomography (PET) with hypercaptation s

111 ds that enable tracking brain amyloid or tau positron emission tomography (PET) with magnetic resonan

112 gh compound B) and tau ((18) F-flortaucipir) positron emission tomography (PET) with prospective neur

113 aromatase availability in the amygdala using positron emission tomography (PET) with the aromatase in

114 quantified DA D1 receptor availability using positron emission tomography (PET) with the radioligand

115 Here, we used positron emission tomography (PET) with the SV2A radioli

116 eta ((18)F-florbetapir or (18)F-florbetaben) positron emission tomography (PET), (18)F-flortaucipir P

117 respectively, were 0.91 and 0.92 for amyloid positron emission tomography (PET), 0.89 and 0.74 for (1

118 tion across the brain of older adults, using positron emission tomography (PET), and investigate how

119 (KOR) availability in the human brain using positron emission tomography (PET), before and after a c

120 mine release at rest using [(11)C]raclopride positron emission tomography (PET), functional connectiv

121 These techniques include positron emission tomography (PET), single-photon emissi

122 In positron emission tomography (PET), the finite range ove

123 Positron emission tomography (PET), traditionally used i

124 We used noninvasive immuno-positron emission tomography (PET), using (89)Zr-labeled

125 (18)F]-fluoro-l-phenylalanine ([(18)F]-DOPA) positron emission tomography (PET), we compared dopamine

126 Using positron emission tomography (PET), we explored the asso

127 Using positron emission tomography (PET), we identified the do

128 hors sought to assess whether (18)F-fluoride positron emission tomography (PET)-computed tomography (

129 The relationship among positron emission tomography (PET)-derived extent of isc

130 On the basis of promising results of positron emission tomography (PET)-directed treatment ap

131 (18)F-PI-2620 is a next generation tau positron emission tomography (PET)-tracer that has demon

132 ides can be used for diagnostic imaging with positron emission tomography (PET).

133 florbetaben (FBB) and 18F-flutemetamol (FMM) positron emission tomography (PET).

134 utoradiography, ex vivo biodistribution, and positron emission tomography (PET).

135 d at developing a tracer for imaging CD80 by positron emission tomography (PET).

136 eased morbidity and mortality.(18)F-fluoride positron emission tomography (PET)/computed tomography (

137 rmine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (

138 (11)C-palmitate and (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (

139 (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (

140 n this study, we sought to develop a bimodal positron emission tomography (PET)/fluorescent imaging a

141 All received an (18)F-DOPA positron emission tomography (PET)/magnetic resonance (M

142 received an integrated (i.e., simultaneous) positron emission tomography (PET)/magnetic resonance im

143 Participants underwent Pittsburgh Compound B Positron Emission Tomography (PiB-PET) to assess fibrill

144 IC) for Fluorine-18 fluorodeoxyglucose (FDG) Positron Emission Tomography - Computed Tomography (PET-

145 Imaging measures of AT(N) (amyloid and tau positron emission tomography [PET]) structural magnetic

146 athology (determined using neuropathology or positron emission tomography [PET]).

147 [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or

148 (18)F-fluorodeoxyglucose positron emission tomography allows for near-universal c

149 Using positron emission tomography and [(18)F]FPEB, we quantif

150 We used [(11)C]FLB 457 positron emission tomography and amphetamine to measure

151 ts for AD] cohort) underwent amyloid and tau positron emission tomography and answered several questi

152 mer Network) study group cohort with amyloid positron emission tomography and behavioral data.

153 on an APOE4 or APOE3 genetic background, by positron emission tomography and by gamma counter.

154 dictions of brain Abeta burden quantified by positron emission tomography and CSF concentrations of A

155 ent rest and vasodilator stress N-13 ammonia positron emission tomography and echocardiography.

156 Brain fluorodeoxyglucose positron emission tomography and information on core fea

157 elopmental advances in imaging tools such as positron emission tomography and magnetic resonance imag

158 Positron emission tomography and microsphere MBF measure

159 Furthermore, the recent advent of tau positron emission tomography and novel fluid-based bioma

160 ethods to measure myocardial blood flow with positron emission tomography and single-photon emission

161 raphy and nuclear imaging techniques such as positron emission tomography and white blood cell scinti

162 supported by cerebrospinal fluid or amyloid positron emission tomography biomarkers.

163 [(11)C]PBR28 Positron Emission Tomography brain imaging of the 18-kDa

164 ultaneous brain imaging with high-resolution positron emission tomography brain imaging.

165 In contrast, biodistribution and positron emission tomography demonstrated strong myocard

166 Longitudinal amyloid small animal positron emission tomography demonstrates accelerated am

167 ars old underwent baseline [(11)C]raclopride positron emission tomography followed by open L-DOPA for

168 MRI and positron emission tomography have shown that neurodegene

169 Coronary (18)F-fluoride positron emission tomography identifies ruptured and hig

170 Gating of positron emission tomography images has been shown to re

171 and [(67)Cu]Cu-MeCOSar-Tz revealed that the positron emission tomography images produced by the form

172 tion of prostate cancer by near-infrared and positron emission tomography imaging after systemic admi

173 orophores to detect myeloid cells by in vivo positron emission tomography imaging and optical modalit

174 Noninvasive positron emission tomography imaging clearly reveals tha

175 protein in brain and lungs using functional positron emission tomography imaging in vivo.

176 Positron emission tomography imaging of the (64)Cu-label

177 tressors in conjunction with high resolution positron emission tomography imaging of the brain.

178 -HT modified NPs is confirmed by noninvasive positron emission tomography imaging studies.

179 on clinical profile, 18F-fluorodeoxyglucose-positron emission tomography imaging, cardiac magnetic r

180 ctreotide[Trp(2-CF(2)(18)F)] enables in vivo positron emission tomography imaging.

181 Bq(124)I-omburtamab was used for radioimmuno-positron emission tomography imaging.

182 oding and amyloid-beta accumulation with PiB-positron emission tomography imaging.

183 structural brain measures using [(11)C]UCB-J positron emission tomography in 18 patients with schizop

184 ctional magnetic resonance imaging and D2/3R positron emission tomography in 51 healthy volunteers, t

185 using the whole-brain analysis technique of positron emission tomography in male mice.

186 an papillomavirus-specific CD8(+) T cells by positron emission tomography in mice bearing human papil

187 We used positron emission tomography in rats to quantify regiona

188 CCR2 positron emission tomography is a promising new biomarke

189 been shown to be accurate when compared with positron emission tomography MBF measured in the same pa

190 ange between pyruvate and lactate but not by positron emission tomography measurements of HK-II-media

191 ve regional genetic effects of voxelwise FDG-positron emission tomography measures between 116 ROIs a

192 ence, photoacoustic, magnetic resonance, and positron emission tomography modalities.

193 0 mg/kg) or saline and then received in vivo positron emission tomography of striatal dopamine synthe

194 report the small molecule, allysine-binding positron emission tomography probe, (68)Ga-NODAGA-indole

195 tomography, magnetic resonance imaging, and positron emission tomography provides important insights

196 nt model and human tissues, using a targeted positron emission tomography radiotracer ((64)Cu-DOTA-EC

197 synthesized and tested the performance of a positron emission tomography radiotracer ((68)Ga-DOTA [1

198 Positron emission tomography revealed that DCZ selective

199 ng procedure can be compressed into a single positron emission tomography scan session lasting less t

200 pressive disorder underwent one [(18)F]FEPPA positron emission tomography scan to measure PFC and ACC

201 Positive positron emission tomography scan was seen in 51% (55/10

202 f laboratory testing, 18F-fluorodeoxyglucose positron emission tomography scan, cardiac magnetic reso

203 d tomography (CT)/magnetic resonance imaging/positron emission tomography scans and at least 10% resp

204 is and activity on [(18)F]fluorodeoxyglucose positron emission tomography scans did not correlate wit

205 y control subjects completed high-resolution positron emission tomography scans with the novel FAAH r

206 In 4 DSP cases with 18F-fluorodeoxyglucose positron emission tomography scans, acute LV myocardial

207 Positron emission tomography studies have demonstrated l

208 Preclinical and human positron emission tomography studies have produced incon

209 We performed [(18) F]-fluorodopa positron emission tomography studies of 57 homozygous an

210 This was confirmed in rat and monkey positron emission tomography studies using [(18)F]9.

211 rospective [(18)F]-dihydroxyphenyl-L-alanine positron emission tomography study in antipsychotic naiv

212 We employed positron emission tomography to measure both dopamine re

213 of drug use or pre-existing traits, we used positron emission tomography to measure mGlu5 receptor a

214 Here we used positron emission tomography to show that MOR levels in

215 [(11)C]NOP-1A positron emission tomography was used to measure the bin

216 [(11)C]FLB 457 and positron emission tomography were used to measure D(2/3)

217 D(2)RO was determined using positron emission tomography with (11)C-raclopride as th

218 ingulate cortex, and prefrontal cortex using positron emission tomography with [(11)C]LY2795050.

219 abolism measured by (18)F-fluorodeoxyglucose positron emission tomography with and without improved s

220 We hypothesized that F-fluorodeoxyglucose positron emission tomography with computed tomography (F

221 F-fluorodeoxyglucose positron emission tomography with CT may noninvasively d

222 DFA metabolism and organ partitioning using positron emission tomography with oral and intravenous l

223 robabilistic reversal learning task and used positron emission tomography with the [(11)C]-(+)-PHNO a

224 hology measured in cerebrospinal fluid or by positron emission tomography(23).

225 1-M) after exposure, echocardiography, micro-positron emission tomography(u-PET), collagen quantifica

226 h lung immunopathology activity, measured by positron emission tomography, and tracked treatment resp

227 in vivo electrophysiology, calcium imaging, positron emission tomography, behavioral efficacy testin

228 years of clinical follow-up and with amyloid positron emission tomography, diffusion tensor imaging,

229 Patients undergoing cardiac stress positron emission tomography, echocardiogram, and renal

230 stribution volume (TSPO V(T)), measured with positron emission tomography, mainly reflects gliosis in

231 On baseline positron emission tomography, patients in the top Lp(a)

232 underwent structural MRI, (18)F-florbetapir positron emission tomography, pure tone audiometry and c

233 compounds described herein are applicable in positron emission tomography, single-photon emission com

234 ttern of annihilation photons detected using positron emission tomography, with respect to anatomical

235 TLG) measured with [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-

236 e accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FD

237 ty of multicancer blood testing coupled with positron emission tomography-computed tomography (PET-CT

238 vity (TGA) on [18]F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT

239 ted these functions in mice and humans using positron emission tomography-computed tomography (PET/CT

240 ctable levels of infection, as determined by positron emission tomography-computed tomography imaging

241 central location, adenocarcinoma, and higher positron emission tomography-computed tomography nodal s

242 was to evaluate the activity of FAP via FAPI-positron emission tomography-computed tomography scans i

243 FAPI-positron emission tomography-computed tomography scans o

244 FAPI-positron emission tomography-computed tomography scans r

245 d for 22 patients after whole-body CT during Positron Emission Tomography-CT.

246 rganoid and cell cultures as well as in vivo positron emission tomography-magnetic resonance imaging

247 ncreased BAT volume and activity measured by positron emission tomography-MRI.

248 chemosensitive to salvage therapy with: (1) positron emission tomography-positive disease or (2) bon

249 ally inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (<= 5 cm) N0

250 onary flow reserve (CFR) was determined from positron emission tomography.

251 ic resonance imaging, and fluorodeoxyglucose-positron emission tomography.

252 h glucose and palmitate tracer infusions and positron emission tomography.

253 al symptom severity in the past month before positron emission tomography.

254 ological evaluation and in vivo studies with positron emission tomography.

255 tery disease underwent serial (18)F-fluoride positron emission tomography.

256 users (8 females), using (11)C-nicotine and positron emission tomography.

257 and MVO(2) were evaluated using 11C-acetate positron emission tomography.

258 althy males and measured brain activity with positron emission tomography.

259 (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-

260 by means of [(18)F]fluoro-2-deoxy-d-glucose Positron Emission Tomography/Computed Tomography ((18)F-

261 assess the role of (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)FD

262 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FD

263 Myocardial perfusion imaging, including positron emission tomography/computed tomography (PET/CT

264 onance imaging, and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT

265 in quantitative (18)F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT

266 enously injected into the mice and imaged by positron emission tomography/computed tomography (PET/CT

267 Fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT

268 the value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT

269 ve total bone imaging (QTBI) using (18)F-NaF positron emission tomography/computed tomography (PET/CT

270 Patients who achieved a complete response by positron emission tomography/computed tomography at thei

271 Dynamic positron emission tomography/computed tomography imaging

272 onium-89-oxine-labeled eosinophils by serial positron emission tomography/computed tomography imaging

273 volume (1000 islets) could be visualized by positron emission tomography/computed tomography imaging

274 Fluorodeoxyglucose positron emission tomography/computed tomography imaging

275 nflammation using (18)F-2-fluorodeoxyglucose-positron emission tomography/computed tomography imaging

276 Patients underwent a 3-month post-CRT positron emission tomography/computed tomography scan an

277 on days 1 and 15, followed by an exploratory positron emission tomography/computed tomography scan.

278 ximab-AVD for 4 to 6 cycles based on interim positron emission tomography/computed tomography scannin

279 ts: The median (range) lung cavity volume on positron emission tomography/computed tomography scans w

280 TMTV was computed on baseline positron emission tomography/computed tomography using t

281 [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography was per

282 [F] fluoro-D-glucose positron emission tomography/computed tomography was use

283 y mass (SULmax) on [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography would p

284 d metabolic activity in the arterial wall on positron emission tomography/computed tomography, indica

285 low reserve (MFR) measured by cardiac (82)Rb-positron emission tomography/computed tomography.

286 dividuals underwent (18)F-fluorodeoxyglucose positron emission tomography/computed tomography; AmygA,

287 %, 80%, and 91% for (18)F-fluorodeoxyglucose positron emission tomography/CT and 60%, 100%, 100%, and

288 (18)F-Fluorodeoxyglucose positron emission tomography/CT and white blood cell sin

289 hybrid (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/magnetic resonance imaging

290 We used simultaneously acquired (11) C-PBR28 positron emission tomography/magnetic resonance imaging

291 We used flortaucipir positron-emission tomography (PET) and florbetapir PET t

292 We previously showed separation of the positron-emission tomography (PET) imaging tracer 3'-deo

293 lves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imag

294 -MRI) near-infrared spectroscopy (NIRS), and positron-emission tomography (PET).

295 ake were assessed by means of static 18F-FDG positron-emission tomography and computed tomography sca

296 eral carotid stenosis of >=50% underwent FDG-positron-emission tomography and NaF-positron-emission t

297 Positron-emission tomography can quantify these processe

298 To date, positron-emission tomography imaging remains the gold st

299 ntified by Cerenkov energy transfer imaging, positron-emission tomography, and fluorescence imaging.

300 ent FDG-positron-emission tomography and NaF-positron-emission tomography.